Skip to main content Skip to main navigation menu Skip to site footer

A rare lipodystrophy syndrome with familial partial lipodystrophy 2 (FPLD2)

  • Hendra Ikhwan Gautama ,
  • Jongky Hendro Prajitno ,


Background: Lipodystrophy (LD) syndromes are a diverse group of ultra-rare diseases characterized by adipose tissue deficiency, resulting in potentially severe metabolic disturbances. Due to their scarcity, diagnosis and management are often challenging for clinicians. This study aimed to report a rare case of LD syndromes, as well their diagnosis and possible management.

Case Presentation: A 27-year-old female presented to Dr. Soetomo General Academic Hospital, Surabaya, Indonesia with a chief complaint of abdominal (epigastric) pain, accompanied by diarrhea, nausea, and vomiting. The patient had a history of uncontrolled type-2 diabetes mellitus (T2DM), dyslipidemia, severe hypertriglyceridemia (HTG), diabetic retinopathy, and glaucoma. Physical examination indicated subcutaneous fat loss, especially from the extremities, and excessive fat accumulation in the face. Hepatosplenomegaly and ascites were detected, further confirmed through abdominal ultrasonography (USG). Laboratory investigations revealed hyperglycemia, dyslipidemia, severe HTG, and renal dysfunction. All of the assessment findings led to the diagnosis of LD syndrome with familial partial lipodystrophy 2 (FPLD2) (Dunnigan syndromes). Therapies included insulin injections and pioglitazone for the treatment of hyperglycemia, simvastatin and fenofibrate to reduce HTG, and some symptomatic drugs to reduce symptoms of the disease. Lifestyle modification (diet and exercise) was recommended to ameliorate metabolic derangements.

Conclusion: There is currently no cure for LD syndrome. Treatment modalities are limited to preventing or reducing severe comorbidities of these syndromes. Increasing knowledge and awareness of the symptoms indicative of LD at an early onset is important.


  1. Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol. 2010/11/16. 2011;7(3):137–50. Available from:
  2. Herranz P, de Lucas R, Pérez-España L, Mayor M. Lipodystrophy syndromes. Dermatol Clin. 2008;26(4):569–ix. Available from:
  3. Huang-Doran I, Sleigh A, Rochford JJ, O’Rahilly S, Savage DB. Lipodystrophy: metabolic insights from a rare disorder. J Endocrinol. 2010;207(3):245–55. Available from:
  4. Mann JP, Savage DB. What lipodystrophies teach us about the metabolic syndrome. J Clin Invest. 2019;129(10):4009–21. Available from:
  5. Akinci G, Celik M, Akinci B. Complications of lipodystrophy syndromes. Presse Med. 2021;50(3):104085. Available from:
  6. Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, et al. The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab. 2016/10/06. 2016;101(12):4500–11. Available from:
  7. Araújo-Vilar D, Santini F. Diagnosis and treatment of lipodystrophy: a step-by-step approach. J Endocrinol Invest. 2019;42(1):61-73. Available from doi: 10.1007/s40618-018-0887-z.
  8. Bagias C, Xiarchou A, Bargiota A, Tigas S. Familial Partial Lipodystrophy (FPLD): Recent Insights. Diabetes Metab Syndr Obes. 2020;13:1531–44. Available from:
  9. Chiquette E, Oral EA, Garg A, Araújo-Vilar D, Dhankhar P. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes. 2017;10:375–83. Available from:
  10. Araújo-Vilar D, Santini F. Diagnosis and treatment of lipodystrophy: a step-by-step approach. J Endocrinol Invest. 2018/04/27. 2019;42(1):61–73. Available from:
  11. Gonzaga-Jauregui C, Ge W, Staples J, Van Hout C, Yadav A, Colonie R, et al. Clinical and Molecular Prevalence of Lipodystrophy in an Unascertained Large Clinical Care Cohort. Diabetes. 2019;69(2):249–58. Available from:
  12. Akinci B, Oral EA, Neidert A, Rus D, Cheng WY, Thompson-Leduc P, et al. Comorbidities and Survival in Patients With Lipodystrophy: An International Chart Review Study. J Clin Endocrinol Metab. 2019;104(11):5120–35. Available from:
  13. Handelsman Y, Oral EA, Bloomgarden ZT, Brown RJ, Chan JL, Einhorn D, et al. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract. 2013;19(1):107–16. Available from:
  14. Kurniawan A, Hariyanto TI. Non-alcoholic fatty liver disease (NAFLD) and COVID-19 outcomes: A systematic review, meta-analysis, and meta-regression. Narra J. 2023;3(1):e102. Available from:
  15. Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2012/12/04. 2013;40(1):195–211. Available from:
  16. Adiputra IMS, Trisnadewi NW, Oktaviani NPW, Dwita DP. Hyperlipidemia is a dominant risk factor for coronary heart disease. J Berk Epidemiol. 2023;11(1):25–31. Available from:
  17. Gupta N, Asi N, Farah W, Almasri J, Barrionuevo P, Alsawas M, et al. Clinical Features and Management of Non-HIV-Related Lipodystrophy in Children: A Systematic Review. J Clin Endocrinol Metab. 2017;102(2):363–74. Available from:
  18. Rahardjo T, Jappi Y, Wibisono S. A rare nasal myiasis in a patient with diabetes mellitus. Bali Med J. 2022;11(3):1784–8. Available from:
  19. Imelda E, Gunawan F. Clinical management of a rare Peters’ anomaly-induced secondary childhood glaucoma: A case report. Narra J. 2021;1(3). Available from:
  20. Polyzos SA, Perakakis N, Mantzoros CS. Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. Metabolism. 2019;96:66–82. Available from:
  21. Pang TCY, Fung T, Samra J, Hugh TJ, Smith RC. Pyogenic liver abscess: an audit of 10 years’ experience. World J Gastroenterol. 2011;17(12):1622–30. Available from:
  22. Goldman M, Chatenoud L. Autoimmune disorders: toward more efficient and safer therapies. Drug Discov Today Ther Strateg. 2009;6(1):1–3. Available from:
  23. Brahm A, Hegele RA. Hypertriglyceridemia. Nutrients. 2013;5(3):981–1001. Available from:
  24. Gelrud A, Whitcomb D, Friedman LGS. Hypertriglyceridemia induced acute pancreatitis managed with low dose intravenous Insulin. Jr Med Res. 2020;23–4. Available from:
  25. Maemunah U. Textbook of internal medicine Ed 2: Faculty of Medicine, Airlangga University, Dr Soetomo Teaching Hospital, Surabaya. 2015: 254 - 60.
  26. Firdausi NL, Artanti KD, Li C-Y. Analysis of Risk Factors Affecting The Occurrence of Chronic Obstructive Pulmonary Disease in Indonesia. J Berk Epidemiol. 2021;9(1):18. Available from:
  27. Suastika K. The challenges of metabolic disorders in Indonesia: focus on metabolic syndrome, prediabetes, and diabetes. Med J Indones. 2020;29(4):350–3. Available from:
  28. Mantzoros C. Lipodystrophic syndromes. In: SpringerReference. Springer-Verlag; Available from:
  29. Pranoto A, Novida H, Prajitno JH, Tjokroprawiro A. Safety and efficacy in early insulin initiation as comprehensive therapy for patients with type 2 diabetes in primary health care centers. Acta Medica Indonesiana. 2015;47(2):104-110.
  30. Wibowo ZK, Mudjanarko SW, Khairina K. The relationship between diabetes distress and HbA1C level in type 2 diabetes mellitus therapy patients: a systematic review. Bali Med J. 2022;11(1):476-84. Available from:

How to Cite

Gautama, H. I., & Prajitno, J. H. . (2023). A rare lipodystrophy syndrome with familial partial lipodystrophy 2 (FPLD2) . Bali Medical Journal, 12(3), 2424–2429.




Search Panel

Hendra Ikhwan Gautama
Google Scholar
BMJ Journal

Jongky Hendro Prajitno
Google Scholar
BMJ Journal